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Abstract
Aims: Metformin may moderate cardiovascular outcomes with dipeptidyl peptidase-4 inhibitors 
(DPP-4i). We examined outcomes of DPP-4i initiation with and without concurrent metformin.
Materials and Methods: We identified Medicare enrollees initiating DPP-4i, sulfonylurea, or 
thiazolidinedione. Using propensity score-weighted Poisson models, we evaluated one-year 
cardiovascular outcome incidence among initiators of DPP-4i versus comparators in subgroups 
with and without concurrent metformin use, and assessed the interaction between initiation drug 
and metformin. Outcomes included mortality, non-fatal myocardial infarction (MI), stroke, and a 
composite.
Results: For the DPP-4i (n=13,391) versus sulfonylurea (n=33,206) comparison, rate differences 
in composite outcome incidence favored DPP-4i: −2.0/100 person-years among metformin users 
(95%CI: −2.7,−1.3) and −1.0 (−1.8,−0.2) among metformin non-users. Similar rate difference 
trends among metformin users and non-users were seen for mortality (−1.5 (−2.1,−0.9) and −0.7 
(−1.4,0.0)) and non-fatal MI (−0.5 (−0.8,−0.3) and 0.1 (−0.2,0.4)). The interaction between 
DPP-4i initiation and metformin was statistically significant for non-fatal MI (p=0.008). For the 
DPP-4i (n=22,210) versus thiazolidinedione (n=9,517) comparison, rate differences in composite 
outcome incidence for DPP-4i initiation were −0.6/100 person-years (−1.5,0.2) among metformin 
users and 1.0 (0.0,2.0) among metformin non-users. Similar rate difference trends among 
metformin users and non-users were seen for mortality (−0.5 (−1.3,0.1) and 0.8 (−0.0,1.7)) and 
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non-fatal MI (−0.1 (−0.4,0.2) and 0.2 (−0.1,0.6)). The interaction between DPP-4i initiation and 
metformin was statistically significant for the composite (p=0.024) and mortality (p=0.023).
Conclusions: Incidence rate differences in multiple cardiovascular outcomes appeared more 
favorable when DPP-4i initiation occurred in the presence of metformin, suggesting a possible 
interaction between DPP-4i and metformin.
Introduction
Metformin is the recommended initial treatment for type 2 diabetes mellitus.(1) Beyond its 
glycemic benefits, metformin does not cause weight gain or hypoglycemia, and may be 
associated with lower mortality.(2,3) Because other diabetes medications are typically added 
to a foundation of metformin therapy, understanding how concurrent metformin use affects 
outcomes with initiation of other agents is important. Currently, interactions between 
metformin and other diabetes medications are poorly understood. Recent years have seen the 
advent of multiple new medication classes for diabetes, raising the urgency of understanding 
how metformin and newer agents interact to affect cardiovascular (CV) outcomes.
Based on a meta-analysis of three CV outcomes trials,(4–6) we recently reported a possible 
interaction between dipeptidyl peptidase-4 inhibitors (DPP-4i) and metformin.(7) While 
concurrent metformin users experienced a trend toward improved CV outcomes with DPP-4i 
use (summary HR 0.92, 95% CI 0.84 to 1.01), metformin non-users showed a trend towards 
harm (HR 1.10, 95% CI 0.97 to 1.26). The difference in overall DPP-4i effect between 
metformin user and non-user subgroups was statistically significant (p=0.036). Because 
there is a physiologic mechanism by which metformin could potentiate the effect of DPP-4i 
– metformin raises levels of glucagon-like peptide-1 (GLP-1),(8,9) and DPP-4i inhibit 
GLP-1 degradation – it is plausible that the two drugs could interact synergistically.
While this novel, hypothesis-generating analysis suggested that metformin use may be a 
moderator of DPP-4i effect on CV outcomes, it had limitations. First, because patient-level 
data were unavailable, we could not account for important potential baseline differences 
between metformin users and non-users. Second, we could not evaluate the moderating 
effects of metformin while comparing DPP-4i to specific alternative agents.
In order to continue exploring the possible interaction between DPP-4i and metformin, we 
used Medicare claims data to examine CV outcomes with initiation of DPP-4i versus two 
other common second-line diabetes therapies (sulfonylurea or thiazolidinedione), both in the 
presence and absence of concurrent metformin use. We then evaluated the statistical 
interaction between drug initiation choice and concurrent metformin use in the overall 
population. Our goal was to examine metformin’s possible moderating effect on CV 
outcomes with DPP-4i initiation, while considering potential baseline population differences 
and specific therapeutic alternatives.
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This retrospective, new-user, active comparator cohort study examined Medicare claims data 
containing longitudinal information about demographics, enrollment, diagnoses, procedures, 
prescription drugs, and mortality for each enrollee.
Study Population
Our study population derived from a 20% random sample of Medicare beneficiaries 
generated by the Centers for Medicare and Medicaid Services (CMS). We identified patients 
aged >65 years with fee-for-service Part A, B, and D enrollment during at least 1 month 
between January 1, 2007 to December 31, 2015. We constructed 4 new-user, active 
comparator cohort pairs after a 1-year washout period: 1) initiators of DPP-4i or 
sulfonylurea with concurrent metformin use; 2) initiators of DPP-4i or sulfonylurea without 
concurrent metformin use; 3) initiators of DPP-4i or thiazolidinedione with concurrent 
metformin use; and 4) initiators of DPP-4i or thiazolidinedione without concurrent 
metformin use. Specific agents included sitagliptin, saxagliptin, linagliptin, and alogliptin 
(DPP-4i); glyburide, glipizide, and glimepiride (sulfonylurea); and pioglitazone and 
rosiglitazone (thiazolidinedione).
We defined each patient’s index date as the first prescription of the drug class of interest 
(DPP-4i, sulfonylurea, or thiazolidinedione) after a 12-month washout. For each active 
comparator cohort pair, prevalent users of the drug classes of interest were excluded. To 
reduce the potential for secondary non-adherence or discontinuation, we restricted our 
cohorts to patients with a second prescription from the originally initiated drug class within 
6 months of the index date. Patient follow-up began at this second fill date. Patients were 
required to have at least 12 months of continuous Medicare Part A, B and D enrollment 
before initiation. Patients with concurrent metformin use were defined as those with days-
supply of metformin on the index date and on the date of the second prescription. Patients 
with no concurrent metformin use were defined as those with no days-supply of metformin 
on the index date and no days-supply plus a grace period (0.5*days-supply of the metformin 
prescription) on the second prescription date. Patients not meeting either of these profiles 
were excluded.
The decision to prescribe metformin may be affected by chronic kidney disease (CKD), 
congestive heart failure (CHF), and long-acting insulin use, potentially leading to 
confounding population differences between concurrent metformin users and non-users. In 
order to: 1) minimize differences between metformin users and non-users; and 2) reduce 
confounding by contraindication in comparing initiation of DPP-4i versus alternative agents, 
we excluded patients with CKD, CHF (including edema, cardiomyopathy, arrhythmia, and 
loop diuretic use), or use of long-acting insulin during the 12 months prior to the index date. 
Supplemental Table 1 lists the International Classification of Diseases, Ninth Revision 
(ICD-9) and Current Procedural Terminology (CPT) codes used in excluding patients with 
CKD and CHF.
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Baseline covariates were examined during the 12 months prior to the index date (inclusive of 
the index date). We examined demographic data, including age, gender, and race/ethnicity. 
We also assessed comorbidities, concurrent use of relevant medications (i.e., the proportion 
of patients with ≥1 prescription during the 12 months prior to the index date) and healthcare 
utilization. Full lists of comorbidity, medication and healthcare utilization covariates are 
provided in Tables 1 and 2.
Outcomes and follow-up
Patient follow-up began at the date of the second prescription for the drug class being 
initiated (DPP-4i versus alternative) and ended at the earliest of the following events: 
outcome occurrence; treatment discontinuation; switching or augmentation; change in 
metformin use status allowing for a grace period of 0.5*days-supply; the end of the 12-
month follow-up period; or December 31, 2015.
Outcomes of interest included a composite of all-cause mortality, non-fatal myocardial 
infarction (MI), and stroke; we chose this outcome in order to replicate the primary outcome 
utilized by recent Food and Drug Administration-mandated CV outcomes trials (4–6). 
Because Medicare claims do not include information on cause of death, we used all-cause 
mortality as a proxy for CV death in our composite; CV deaths account for >50% of all-
cause mortality in patients with diabetes. We also individually evaluated all-cause mortality, 
as well as non-fatal MI, and stroke (censoring for mortality). We used validated ICD-9-based 
definitions for non-fatal MI (code 410 in the first or second position of inpatient claims) and 
stroke (codes 430, 431, 433.x1, 434.x1, or 436 in the first position of inpatient claims).
(10,11)
Analysis
In order to determine whether metformin is a moderator of CV outcomes with initiation of 
DPP-4i, we first compared DPP-4i to each active comparator agent (sulfonylurea or 
thiazolidinedione) using separate, weighted Poisson regression models in subgroups with 
and without concurrent metformin use. Using all baseline covariates, we created logistic 
regression models to estimate subgroup-specific propensity scores predicting initiation of 
DPP-4i versus sulfonylurea in the presence and absence of concurrent metformin, and 
DPP-4i versus thiazolidinedione in the presence and absence of metformin.(12) In each 
analysis, we assigned a weight of ‘1’ to DPP-4i initiators and a weight of ‘propensity 
score/[1 − propensity score]’ to initiators of sulfonylurea or thiazolidinedione. This created 
pseudo-populations of patients initiating sulfonylurea and thiazolidinedione with similar 
covariate distribution to those initiating DPP-4i.(13,14) Each weighted Poisson regression 
model utilized a bootstrap variance estimator to determine 95% confidence intervals for CV 
outcome rate differences. These analyses thus explored what would have happened to 
DPP-4i initiators had they instead initiated sulfonylurea or thiazolidinedione, both in the 
presence and absence of concurrent metformin.(15)
Next, we evaluated interaction terms between drug initiation choice (DPP-4i versus 
sulfonylurea or DPP-4i versus thiazolidinedione) and concurrent metformin use in each 
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population. Interaction analyses were based on the weighted 12-month absolute rate 
differences between DPP-4i and comparator estimated using weighted Poisson regression 
models, with propensity scores estimated in the overall population with or without 
concurrent metformin.
Sensitivity Analyses
Prescribing patterns in diabetes have changed over time,(16) which could have affected drug 
initiation patterns and CV outcomes during the study period. We therefore conducted 
sensitivity analyses adjusting for the impact of calendar year. In these analyses, we re-
estimated propensity scores accounting for calendar year of initiation, and recalculated CV 
outcome rate differences for DPP-4i versus comparators (using methods above) with the re-
estimated propensity scores. Of note, we did not adjust for calendar year in our primary 
analysis because we have previously suggested that calendar year is an instrumental variable 
in studies of CV outcomes with initiation of DPP-4i versus thiazodinedione;(17) 
conditioning for instrumental variables in propensity scores can increase bias and variance, 
so should be avoided.(18–20)
Results
Baseline Characteristics
For the DPP-4i versus sulfonylurea comparison, we identified 8,665 DPP-4i initiators and 
18,420 sulfonylurea initiators with concurrent metformin use. Among metformin non-users, 
we identified 4,726 DPP-4i initiators and 14,786 sulfonylurea initiators. Baseline 
characteristics were generally similar between initiators of DPP-4i and sulfonylurea within 
each metformin subgroup and any remaining differences were balanced by weighting using 
subgroup-specific propensity scores (Table 1).
For the DPP-4i versus thiazolidinedione comparison, we identified 15,141 DPP-4i initiators 
and 5,983 thiazolidinedione initiators with concurrent metformin use. Among metformin 
non-users, we identified 7,069 DPP-4i initiators and 3,834 thiazolidinedione initiators. 
Baseline characteristics were generally similar between initiators of DPP-4i and 
thiazolidinedione within each metformin subgroup and any remaining differences were 
balanced by weighting (Table 2).
Incidence of CV outcomes with initiation of DPP-4i versus sulfonylurea among concurrent 
metformin users and non-users
For the comparison of DPP-4i versus sulfonylurea, outcomes generally favored DPP-4i 
initiation regardless of metformin use (Table 3). One-year incidence of the composite 
outcome ranged from 3.4–5.6 per 100 person-years across groups; the rate difference with 
DPP-4i versus sulfonylurea was −2.0 per 100 person-years (95% CI: −2.7 to −1.3) among 
metformin users and −1.0 (−1.8 to −0.2) among metformin non-users. For all-cause 
mortality, one-year incidence ranged from 2.6–4.4 per 100 person-years across groups; the 
rate difference with DPP-4i versus sulfonylurea was −1.5 per 100 person-years (−2.1 to 
−0.9) among metformin users and −0.7 (−1.4 to 0.0) among metformin non-users. For non-
fatal MI, one-year incidence ranged from 0.4–1.0 per 100 person-years across groups; the 
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rate difference with DPP-4i versus sulfonylurea was −0.5 per 100 person-years (−0.8 to 
−0.3) among metformin users and 0.1 (−0.2 to 0.4) among metformin non-users. For stroke, 
one-year incidence ranged from 0.3–0.8 per 100 person-years across groups; the rate 
difference with DPP-4i versus sulfonylurea was −0.1 per 100 person-years (−0.3 to 0.1) 
among metformin users and −0.5 (−0.7 to −0.2) among metformin non-users.
For the composite outcome, mortality, and non-fatal MI, rate differences appeared to more 
strongly favor DPP-4i initiation (over sulfonylurea) among concurrent metformin users. The 
interaction between drug initiation choice and metformin use was statistically significant for 
non-fatal MI (p=0.008) (Table 4). Thus, patients initiating DPP-4i rather than sulfonylurea 
experienced a significantly more favorable rate difference for non-fatal MI with concurrent 
metformin than in the absence of metformin.
Initiation of DPP-4i versus thiazolidinedione among concurrent metformin users and non-
users
For the comparison of DPP-4i versus thiazolidinedione, most outcomes trended toward 
favoring DPP-4i initiation among concurrent metformin users, and toward thiazolidinedione 
initiation among metformin non-users (Table 3). For the composite outcome, one-year 
incidence ranged from 3.4–4.5 per 100 person-years across groups; the rate difference with 
DPP-4i versus thiazolidinedione was −0.6 per 100 person-years (95% CI: −1.5 to 0.2) 
among concurrent metformin users and 1.0 (0.0 to 2.0) among metformin non-users. One-
year incidence of all-cause mortality ranged from 2.4–3.5 per 100 person-years across 
groups; the rate difference with DPP-4i versus thiazolidinedione was −0.5 per 100 person-
years (−1.3 to 0.1) among metformin users and 0.8 (−0.0 to 1.7) among metformin non-
users. For non-fatal MI, one-year incidence ranged from 0.6–0.8 per 100 person-years across 
groups; the rate difference with DPP-4i versus thiazolidinedione was −0.1 per 100 person-
years (−0.4 to 0.2) among metformin users and 0.2 (−0.1 to 0.6) among metformin non-
users. One-year stroke incidence ranged from 0.5–0.7 per 100 person-years across groups, 
but rates did not differ between DPP-4i and thiazolidinedione initiators regardless of 
metformin use.
For the composite outcome, mortality, and non-fatal MI, rate differences appeared to favor 
DPP-4i initiation (over thiazolidinedione) among concurrent metformin users. The 
interaction between drug initiation choice and metformin use was statistically significant for 
the composite outcome (p=0.024) and all-cause mortality (p=0.023) (Table 4). Thus, patients 
initiating DPP-4i rather than thiazolidinedione experienced significantly more favorable rate 
differences for the composite outcome and mortality with concurrent metformin than in the 
absence of metformin.
Sensitivity Analyses
Results from the sensitivity analyses incorporating adjustment for initiation year yielded 
similar results for the DPP-4i versus sulfonylurea comparison. Results for the DPP-4i versus 
thiazolidinedione comparison varied modestly in magnitude and precision for most 
outcomes, but also changed direction in some cases (Supplemental Table 2); for example, 
among concurrent metformin users, the one-year rate difference for the composite outcome 
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was −0.6 per 100 person-years (−1.5 to 0.2) favoring DPP-4i in the primary analysis, but 
changed to 0.2 (−0.8 to 1.1) favoring thiazolidinedione in the sensitivity analysis adjusting 
for calendar year.
Discussion
This analysis explored whether concurrent metformin use moderates the effect of DPP-4i 
initiation on CV outcomes. Initiating DPP-4i rather than sulfonylurea was associated with 
lower one-year rates of multiple CV outcomes overall, but rate differences more strongly 
favored DPP-4i in the presence of metformin. For non-fatal MI, the interaction between drug 
initiation choice and metformin use was statistically significant. Initiating DPP-4i rather than 
thiazolidinedione was associated with favorable rate differences for multiple CV outcomes 
in the presence of concurrent metformin, but unfavorable rate differences in the absence of 
metformin. For the composite outcome and all-cause mortality, the interaction between drug 
initiation choice and metformin use was statistically significant. Overall, these hypothesis-
generating findings support the possibility that CV outcomes with DPP-4i may be more 
favorable in the presence of metformin than in its absence.
Sensitivity analyses adjusting for calendar year of initiation did not meaningfully change 
results for the DPP-4i versus sulfonylurea comparison, but did affect results for some 
outcomes for the DPP-4i versus thiazolidinedione comparison. We have previously reported 
that calendar year strongly predicts initiation of DPP-4i versus thiazolidinedione and argued 
for its use as instrumental variable with respect to CV outcomes; therefore, the observed 
changes in our sensitivity analyses can be explained by adjustment for the calendar year 
instrument.(18) It is for this reason that we did not include calendar year in our primary 
analyses.
Our findings regarding interactions between drug initiation choice (DPP-4i versus 
alternatives) and metformin status are consistent with – and could potentially underlie – the 
results of our recent meta-analysis.(7) The present analysis used real-world data and 
rigorous methodology to build upon our prior findings by addressing weaknesses of the 
meta-analysis. We minimized important potential population differences between metformin 
users and non-users by restricting to patients without CKD, CHF and long-acting insulin 
use. Our use of restriction and a new-user, active comparator design helps balance baseline 
risk of outcomes and key confounders, and also likely reduces unmeasured confounding. 
Further remaining imbalances in measured covariates were mitigated by using propensity 
score-based weighting. We were also able to explore the interaction between DPP-4i 
initiation and metformin status with consideration of individual comparator agents and 
specific CV outcomes.
Prior randomized trials have indicated that DPP-4i exert a neutral effect on CV outcomes 
versus placebo.(4–6,21) While an ongoing trial is comparing the effects of a DPP-4i 
(linagliptin) and a sulfonylurea (glimepiride) on CV outcomes,(22) randomized trial data 
comparing DPP-4i to active comparators are limited. Consistent with our current findings, 
multiple observational studies have suggested that DPP-4i may be associated with improved 
CV outcomes relative to sulfonylurea.(23–25) Also consistent with our results, observational 
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studies show similar rates of CV outcomes with DPP-4i and thiazolidinedione,(24) or even 
increased rates of some outcomes with DPP-4i.(26,27) However, prior studies have not 
specifically examined how metformin interacts with DPP-4i to affect outcomes. Our findings 
therefore extend the existing literature by exploring the interaction between DPP-4i and 
metformin.
Although the average treatment effect of DPP-4i in randomized trials appears neutral, it is 
increasingly understood that trial-reported average treatment effects often conceal variability 
in results experienced by patient subgroups.(28,29) One potential contributor to 
heterogeneity of treatment effect in diabetes trials is interactions between co-prescribed 
medications. Currently, how different medication classes interact to determine CV outcomes 
in type 2 diabetes is poorly understood. Since metformin is the consensus first-line medical 
treatment for type 2 diabetes,(1) recognizing how its presence impacts the effectiveness of 
next-line agents like DPP-4i could inform clinical practice and guideline development. 
Because there exists a potential GLP-1-based mechanism by which metformin could 
enhance the effect of DPP-4i,(8,9) DPP-4i provide a sensible opportunity to study 
interactions with metformin.
For multiple CV outcomes, initiation of DPP-4i rather than sulfonylurea was associated with 
a more pronounced risk difference in the presence of metformin; the interaction between 
drug initiation choice and concurrent metformin status was statistically significant for non-
fatal MI. Similarly, initiation of DPP-4i rather than thiazolidinedione tended to be associated 
with more favorable risk differences in the presence of metformin; the interaction between 
drug initiation choice and concurrent metformin status was statistically significant for the 
composite outcome and all-cause mortality. Taken together, these findings provide support 
for the concept that physiologic interactions between certain medication classes may affect 
specific CV outcomes and contribute to the heterogeneity of treatment effect seen in 
randomized trials. If confirmed, our results may provide a rationale for using DPP-4i 
specifically in conjunction with metformin.
While our findings offer support for a possible advantageous interaction between DPP-4i 
and metformin, an alternative interpretation is that metformin could instead have deleterious 
interactions with the comparator agents. The higher absolute rates of the composite outcome 
and mortality among sulfonylurea and thiazolidinedione initiators with concurrent 
metformin use (as compared to initiators without concurrent metformin) may support this 
alternative. Observational studies suggest that the combination of metformin and 
sulfonylurea may be associated with higher CV risk,(30) and early addition of metformin to 
sulfonylurea was associated with increased risk of death in the United Kingdom Prospective 
Diabetes Study.(31) We know of no analogous data regarding the combination of metformin 
and thiazolidinedione. While a deleterious metformin-comparator interaction cannot be 
dismissed, the physiologic plausibility of a favorable interaction between DPP-4i and 
metformin, along with the general consistency of our sulfonylurea and thiazolidinedione 
analyses, supports our primary interpretation.
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We focused exclusively on Medicare beneficiaries aged >65 years with fee-for-service Part 
A, B, and D enrollment, which may limit the generalizability of our findings. Because we 
specifically examined new users of DPP-4i and comparator drugs in order to minimize 
prevalent-user biases, our findings likewise may not generalize to patients on complex 
regimens.
Although we minimized important differences between metformin users and non-users by 
attempting to exclude patients with CKD, CHF, and long-acting insulin use, individuals with 
mild and/or unrecognized CKD or CHF may have been included in our analytic sample. 
Other unaccounted-for differences between metformin users and non-users may also have 
been present. It is therefore possible that factors other than metformin use alone may explain 
the observed differences in DPP-4i effect between concurrent metformin users and non-
users.
Medicare claims do not contain variables like body mass index and smoking, so we were 
unable to directly adjust for these factors in examining the relationship between drug 
initiation choice and CV outcomes. However, previous studies have shown that these 
variables do not affect the choice to initiate of DPP-4i versus sulfonylurea or 
thiazolidinedione,(32) so are unlikely to be strong confounders. In this Medicare population, 
mortality contributed strongly to our composite outcome. We did not account for intervening 
mortality when examining the risk of individual CV outcomes at one year.
We used ICD-9 codes to ascertain non-fatal MI and stroke events in this study. CMS 
implemented use of the International Classification of Diseases, Tenth Revision (ICD-10) on 
October 1, 2015. As such, some unaccounted-for non-fatal MI and stroke events may have 
occurred during the final 3 months of the 2007–2015 observation period. This issue did not 
impact mortality ascertainment, and is unlikely to have substantively affected our findings. 
Additionally, we confined follow-up to 12 months. While this choice minimizes the 
likelihood of undetected secondary non-adherence or downstream discontinuation, 
restricting follow-up may have limited detection of between-group differences that emerge 
over time.
Of note, specific agents within the DPP-4i class may interact with metformin differently. 
Future research should further examine metformin’s moderating effects on individual 
DPP-4i agents, and also explore how metformin may interact with other novel medication 
classes.
Conclusions
Consistent with the findings from our recent meta-analysis, we found evidence for 
interactions between drug initiation choice (DPP-4i versus alternative agents) and concurrent 
metformin use with regard to some CV outcomes. Beyond the potential clinical implications 
of metformin’s potential moderating effect on CV outcomes with DPP-4i initiation, this 
analysis supports the concept that physiologic interactions between medication classes may 
affect outcomes, and argues for further investigation of interactions between commonly-used 
medications for type 2 diabetes.
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Table 3.
Comparison of subgroup-weighted, one-year outcome incidence after initiation of DPP-4i versus comparator 
drugs in the presence or absence of concurrent metformin use.
Concurrent metformin users Concurrent metformin non-users
DPP-4i vs. sulfonylurea 
outcome
Incidence per 100 
patient-years†
(95% CI)
ARD with DPP-4i vs. 
sulfonylurea
(95% CI)
Incidence per 100 
patient-years†
(95% CI)




 DPP-4i 3.7 (3.1 to 4.2) −2.0 (−2.7 to −1.3) 3.4 (2.9 to 4.1) −1.0 (−1.8 to −0.2)
 Sulfonylurea 5.6 (5.2 to 6.1) 4.5 (4.0 to 5.0)
All-cause mortality
 DPP-4i 2.9 (2.4 to 3.4) −1.5 (−2.1 to −0.9) 2.6 (2.1 to 3.2) −0.7 (−1.4 to 0.0)
 Sulfonylurea 4.4 (4.0 to 4.8) 3.3 (2.9 to 3.7)
Non-fatal MI
 DPP-4i 0.4 (0.2 to 0.6) −0.5 (−0.8 to −0.3) 0.7 (0.5 to 1.1) 0.1 (−0.2 to 0.4)
 Sulfonylurea 1.0 (0.8 to 1.2) 0.7 (0.5 to 0.8)
Stroke
 DPP-4i 0.4 (0.3 to 0.6) −0.1 (−0.3 to 0.1) 0.3 (0.1 to 0.5) −0.5 (−0.7 to −0.2)




Incidence per 100 
patient-years†
(95% CI)
ARD with DPP-4i vs. 
thiazolidinedione
(95% CI)
Incidence per 100 
patient-years†
(95% CI)




 DPP-4i 3.9 (3.5 to 4.3) −0.6 (−1.5 to 0.2) 4.4 (3.9 to 5.0) 1.0 (0.0 to 2.0)
 Thiazolidinedione 4.5 (3.8 to 5.2) 3.4 (2.7 to 4.2)
All-cause mortality
 DPP-4i 2.9 (2.6 to 3.3) −0.5 (−1.3 to 0.1) 3.3 (2.8 to 3.8) 0.8 (−0.0 to 1.7)
 Thiazolidinedione 3.5 (2.9 to 4.1) 2.4 (1.8 to 3.1)
Non-fatal MI
 DPP-4i 0.6 (0.5 to 0.8) −0.1 (−0.4 to 0.2) 0.8 (0.6 to 1.1) 0.2 (−0.1 to 0.6)
 Thiazolidinedione 0.7 (0.4 to 1.0) 0.6 (0.3 to 0.9)
Stroke
 DPP-4i 0.5 (0.3 to 0.6) −0.0 (−0.3 to 0.2) 0.7 (0.5 to 0.9) 0.0 (−0.4 to 0.5)
 Thiazolidinedione 0.5 (0.3 to 0.8) 0.6 (0.3 to 1.0)




Composite outcome includes all-cause mortality, non-fatal MI, and stroke
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Table 4.
Analysis of interaction between concurrent metformin use/non-use and initiation of DPP-4i versus comparator 
drugs for subgroup-weighted one-year outcomes.
Outcome Parameter estimate for interaction between metformin status and initiation drug Interaction term p-value
DPP-4i vs. sulfonylurea
Composite outcome† −0.15 (−0.41 to 0.12) 0.290
All-cause mortality −0.16 (−0.47 to 0.16) 0.334
Non-fatal MI −0.92 (−1.60 to −0.24) 0.008
Stroke 0.87 (−0.02 to 1.77) 0.055
DPP-4i vs. thiazolidinedione
Composite outcome† −0.38 (−0.71 to −0.05) 0.024
All-cause mortality −0.44 (−0.83 to −0.06) 0.023
Non-fatal MI −0.41 (−1.15 to 0.33) 0.282
Stroke −0.08 (−0.97 to 0.80) 0.863
Abbreviations: DPP-4i=dipeptidyl peptidase-4 inhibitor; MI=myocardial infarction
†
Composite outcome includes all-cause mortality, non-fatal MI, and stroke
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